Frankfurt - Delayed Quote EUR

Silence Therapeutics plc (XRP2.F)

4.5200

+0.2400

+(5.61%)

At close: June 13 at 9:15:05 AM GMT+2

Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera

LONDON, June 12, 2025--Silence Therapeutics plc ("Silence" or the "Company") (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today presented additional data showcasing the SANRECO Phase 1 study of divesiran in patients with polycythemia vera (PV) at the European Hematology Association (EHA) 2025 Annual Meeting in Milan, Italy.

Business Wire yesterday

SLN

SLNCF
One Silence Therapeutics Insider Raised Stake By 15% In Previous Year

Viewing insider transactions for Silence Therapeutics plc's ( NASDAQ:SLN ) over the last year, we see that insiders...

Simply Wall St. yesterday

SLN

SLNCF
Wall Street Analysts Think Silence Therapeutics (SLN) Could Surge 556.19%: Read This Before Placing a Bet

The consensus price target hints at a 556.2% upside potential for Silence Therapeutics (SLN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks 7 days ago

SLNCF
Wall Street Analysts Believe Silence Therapeutics (SLN) Could Rally 590.66%: Here's is How to Trade

The mean of analysts' price targets for Silence Therapeutics (SLN) points to a 590.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks 23 days ago

SLNCF
Spotlight On Silence Therapeutics And 2 Other Promising Penny Stocks

Over the last 7 days, the United States market has risen by 4.5%, contributing to an overall increase of 11% over the past year, with earnings forecasted to grow annually by 14%. For investors looking beyond well-known names, penny stocks—often smaller or newer companies—can present surprising opportunities. Despite being a somewhat outdated term, these stocks remain relevant as they can offer both value and growth potential when backed by strong financials and a clear growth path.

Simply Wall St. 28 days ago

MX

CABA

SLN
We're Keeping An Eye On Silence Therapeutics' (NASDAQ:SLN) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Simply Wall St. last month

SLN

SLNCF
Silence Therapeutics First Quarter 2025 Earnings: Misses Expectations

Silence Therapeutics ( NASDAQ:SLN ) First Quarter 2025 Results Key Financial Results Revenue: US$142.0k (down 99% from...

Simply Wall St. last month

SLN

SLNCF
Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

LONDON, May 08, 2025--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial results for the first quarter ended March 31, 2025, and reviewed recent business highlights.

Business Wire last month

SLN

SLNCF
Silence Therapeutics Welcomes Tim McInerney to Board of Directors

LONDON, May 06, 2025--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced the appointment of Tim McInerney to the Company’s Board of Directors, effective immediately. Mr. McInerney will stand for re-appointment to the Silence Board at the Annual General Meeting ("AGM") in June 2025.

Business Wire last month

SLN

SLNCF
Silence Therapeutics plc (SLN): Among Takeover Rumors Hedge Funds Are Buying

We recently published a list of 20 Takeover Rumors Hedge Funds Are Buying. In this article, we are going to take a look at where Silence Therapeutics plc (NASDAQ:SLN) stands against other takeover rumor stocks hedge funds are buying. Hedge funds tend to pile up on a stock that gains or is expected to gain […]

Insider Monkey last month

SLNCF
3 Promising Penny Stocks With Market Caps Under $200M

Over the last 7 days, the U.S. market has dropped 3.0%, yet it remains up by 4.6% over the past year, with earnings forecasted to grow annually by 14%. In light of these conditions, identifying stocks with strong balance sheets and solid fundamentals becomes crucial for investors seeking growth opportunities. Penny stocks, often representing smaller or newer companies, may seem like a relic from earlier market trends but continue to offer potential for significant upside at lower price points.

Simply Wall St. last month

SLN

SLNCF

ICAD
Silence Therapeutics plc (NASDAQ:SLN): When Will It Breakeven?

Silence Therapeutics plc ( NASDAQ:SLN ) is possibly approaching a major achievement in its business, so we would like...

Simply Wall St. 2 months ago

SLN

SLNCF
Revenue Downgrade: Here's What Analysts Forecast For Silence Therapeutics plc (NASDAQ:SLN)

Today is shaping up negative for Silence Therapeutics plc ( NASDAQ:SLN ) shareholders, with the analysts delivering a...

Simply Wall St. 3 months ago

SLN

SLNCF
Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference

LONDON, March 05, 2025--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that management will present a company overview at the Leerink Partners Global Healthcare Conference on Wednesday, March 12th at 1:00 p.m. ET.

Business Wire 3 months ago

SLN

SLNCF
Silence Therapeutics (SLN) Upgraded to Buy: Here's What You Should Know

Silence Therapeutics (SLN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks 3 months ago

SLNCF
Silence Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Silence Therapeutics ( NASDAQ:SLN ) Full Year 2024 Results Key Financial Results Revenue: UK£43.3m (up 71% from FY...

Simply Wall St. 3 months ago

SLN

SLNCF
Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

LONDON, February 27, 2025--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial results for the full year ended December 31, 2024, and provided a business update.

Business Wire 3 months ago

SLN

SLNCF
Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025

LONDON, February 13, 2025--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that the Company will release its financial and business results for the fourth quarter and full year ended December 31, 2024, on Thursday, February 27, 2025.

Business Wire 3 months ago

SLN

SLNCF
Institutional owners may take dramatic actions as Silence Therapeutics plc's (NASDAQ:SLN) recent 14% drop adds to one-year losses

Key Insights Given the large stake in the stock by institutions, Silence Therapeutics' stock price might be vulnerable...

Simply Wall St. 4 months ago

SLN

SLNCF
Silence Therapeutics plc (SLN): Among the Oversold Global Stocks to Buy Right Now

We recently compiled a list of the 10 Oversold Global Stocks To Buy Right Now. In this article, we are going to take a look at where Silence Therapeutics plc (NASDAQ:SLN) stands against the other oversold global stocks. ‘There are decades where nothing happens, and there are weeks where decades happen” is apt when starting a […]

Insider Monkey 5 months ago

SLNCF

^FTSE

Performance Overview

Return	XRP2.F	S&P 500 (^GSPC)
YTD	-30.99%	+1.62%
1-Year	-75.16%	+10.00%
3-Year	-45.21%	+59.40%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Silence Therapeutics plc (XRP2.F)

Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera

One Silence Therapeutics Insider Raised Stake By 15% In Previous Year

Wall Street Analysts Think Silence Therapeutics (SLN) Could Surge 556.19%: Read This Before Placing a Bet

Wall Street Analysts Believe Silence Therapeutics (SLN) Could Rally 590.66%: Here's is How to Trade

Spotlight On Silence Therapeutics And 2 Other Promising Penny Stocks

We're Keeping An Eye On Silence Therapeutics' (NASDAQ:SLN) Cash Burn Rate

Silence Therapeutics First Quarter 2025 Earnings: Misses Expectations

Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

Silence Therapeutics Welcomes Tim McInerney to Board of Directors

Silence Therapeutics plc (SLN): Among Takeover Rumors Hedge Funds Are Buying

3 Promising Penny Stocks With Market Caps Under $200M

Silence Therapeutics plc (NASDAQ:SLN): When Will It Breakeven?

Revenue Downgrade: Here's What Analysts Forecast For Silence Therapeutics plc (NASDAQ:SLN)

Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference

Silence Therapeutics (SLN) Upgraded to Buy: Here's What You Should Know

Silence Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025

Institutional owners may take dramatic actions as Silence Therapeutics plc's (NASDAQ:SLN) recent 14% drop adds to one-year losses

Silence Therapeutics plc (SLN): Among the Oversold Global Stocks to Buy Right Now

Performance Overview